Skip to main content
Home

Epocrates Online Contact us

  • Explore features
  • Reach clinicians
  • Buy now
By vgreene, 26 March, 2021

Tx recommendations1 5

By vgreene, 26 March, 2021

Duration long term

By vgreene, 26 March, 2021

Range 2 5 3 5

By vgreene, 26 March, 2021

Target INR 3 0

By vgreene, 26 March, 2021

Clinical considerations1 4

By vgreene, 26 March, 2021

Pts w rheumatic MS or mechanical prosthesis should be anticoagulated

By vgreene, 26 March, 2021

Pts w native valvular heart dz excluding rheumatic mitral stenosis or who received bioprosthetic valve 3mo ago Use shared decision making process based on the CHA2DS2 VASc score

By vgreene, 26 March, 2021

Other considerations1 3

By vgreene, 26 March, 2021

Duration extended

By vgreene, 26 March, 2021

Range 2 0 3 0

Pagination

  • First page
  • Previous page
  • …
  • Page 1127
  • Page 1128
  • Page 1129
  • Page 1130
  • Current page 1131
  • Page 1132
  • Page 1133
  • Page 1134
  • Page 1135
  • …
  • Next page
  • Last page

About Us

  • Company Overview
  • Media Relations
  • Contact
  • Editorial Policy
  • Editorial Process
  • Third-Party Sponsorship Policy
  • athenahealth

Products

  • Core Products
  • Mobile CME
  • Product Licenses

Business Solutions

  • Pharma
  • Market Research
  • Institutions

Support

  • Support Center
  • Install
  • My Account

Stay Connected

Facebook Twitter YouTube

Patient Resource Footer Bottom

  • Privacy Policy
  • Terms of Use
  • Site Map